Skip to main content

Table 1 Baseline characteristics of enrolled patients and group comparison according to the type of ULD used

From: Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort

  Whole sample (n = 245) Allopurinol (n = 208) Febuxostat (n = 35) P
Age (years), mean (SD) 63.5 (13.5) 62.1 (13.2) 72.2 (11.8) < 0.001
Male 212 (86.5) 189 (90.9) 22 (62.9) < 0.001
HT 169 (69.0) 137 (65.9) 30 (85.7) 0.019
DM 60 (24.5) 47 (22.6) 13 (37.1) 0.065
DL 128 (52.2) 107 (51.4) 20 (57.1) 0.532
Smoking background (n = 234) 140 (59.9) 128 (64.3) 12 (36.4) 0.006
CVD 61 (24.9) 45 (21.6) 16 (45.7) 0.002
Diuretic therapy 109 (44.5) 86 (41.3) 23 (65.7) 0.007
Type of diuretics (n = 243)     0.005
 Thiazides 61 (25.1) 51 (24.5) 10 (28.6)  
 Loop agents 46 (18.9) 33 (15.9) 13 (37.1)
Combination of diuretics 11 (4.5) 7 (3.4) 4 (11.4) 0.057
BMI (kg/m2), mean (SD) 29.9 (5.2) 30.0 (5.0) 30.2 (6.0) 0.790
eGFR (mL/min), mean (SD) (n = 243) 71.5 (26.4) 76.6 (23.4) 40.8 (23.0) < 0.001
Chronic kidney disease (n = 241) 76 (31.5) 47 (22.8) 29 (82.9) < 0.001
SU (mg/dL), mean (SD) 8.3 (1.7) 8.2 (1.4) 9.3 (2.4) 0.008
Prior use of ULD (n = 243) 58 (23.9) 50 (24.1) 8 (22.9) 0.914
  1. Data shown as number (percentage) unless otherwise specified. In bold, statistically significant differences between allopurinol and febuxostat groups. BMI body mass index, calculated as weight: (height)2, CVD cardiovascular disease, DL dyslipidaemia, DM diabetes mellitus, HT hypertension, SD standard deviation, SU serum urate, ULD urate-lowering drugs